Cognitive Function in Primary Sjögren's Syndrome: A Systematic Review.
brain fog
cognitive functions
dementia
fatigue
mild cognitive impairment
primary Sjögren’s syndrome
systematic review
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
15 Apr 2019
15 Apr 2019
Historique:
received:
18
03
2019
revised:
03
04
2019
accepted:
09
04
2019
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
18
4
2019
Statut:
epublish
Résumé
Cognitive disorders are reported to be common in patients with primary Sjogren's syndrome (pSS). In some cases, they are the first clinical manifestation, preceding the diagnosis of pSS by two years on average. A systematic review was conducted to explore cognitive impairment in pSS, with reference to diagnostic methods and their relationship with laboratory data and clinical manifestations. According to the PRISMA 2009 checklist, we carried out a comprehensive literature search in the three main bibliographic databases: MEDLINE, EMBASE, and PsycINFO (NICE HDAS interface). The following main search terms were used: primary Sjogren syndrome, neurological manifestations, fatigue, cognitive functions, psychiatric manifestations, mild cognitive impairment, dementia, and neurocognitive disorder. The search was made on 14 September, 2018. References from all selected studies were also examined. Inclusion criteria were: all studies and case-reports published in any language from 2002 that assessed the association of pSS (according to classification criteria proposed by the 2002 American/European collaborative group (AECG)) with all types of cognitive impairment (including dementia). Exclusion criteria were: reviews, abstracts, secondary Sjögren's syndrome (SS), and all articles in which other classification criteria were used. The initial search yielded 352 articles, of which 253 were excluded based on the title and abstract review. A total of 54 articles underwent a full-length review, and 32 articles were excluded. Data were extracted from 18 studies and three case-reports involving a total of 6196 participants. In most cases, cognitive dysfunction was a brain fog or a mild cognitive impairment (MCI). Occasionally, an autoimmune dementia was present. The relationship between pSS and degenerative dementias, such as Alzheimer's disease (AD), was a controversial issue, even if some investigators hypothesized that pSS could be a risk factor. Several unmet needs were highlighted. First, some of the included studies had not reported the severity of pSS; hence, few correlations between disease severity and cognitive function were possible. Secondly, the evaluation of the pathogenetic role of comorbid diseases was often absent. The lack of information on the type of dementia represented a third critical point in the majority of the included studies. This systematic review confirmed that adequate studies on cognitive function in pSS are scarce, mostly performed on small-sized samples, and often conflicting. The routine assessment of cognitive function in patients with pSS seems advisable and it will help to elucidate some of the unmet needs highlighted by this review in future appropriately designed studies.
Sections du résumé
BACKGROUND
BACKGROUND
Cognitive disorders are reported to be common in patients with primary Sjogren's syndrome (pSS). In some cases, they are the first clinical manifestation, preceding the diagnosis of pSS by two years on average.
AIM
OBJECTIVE
A systematic review was conducted to explore cognitive impairment in pSS, with reference to diagnostic methods and their relationship with laboratory data and clinical manifestations.
MATERIALS AND METHODS
METHODS
According to the PRISMA 2009 checklist, we carried out a comprehensive literature search in the three main bibliographic databases: MEDLINE, EMBASE, and PsycINFO (NICE HDAS interface). The following main search terms were used: primary Sjogren syndrome, neurological manifestations, fatigue, cognitive functions, psychiatric manifestations, mild cognitive impairment, dementia, and neurocognitive disorder. The search was made on 14 September, 2018. References from all selected studies were also examined. Inclusion criteria were: all studies and case-reports published in any language from 2002 that assessed the association of pSS (according to classification criteria proposed by the 2002 American/European collaborative group (AECG)) with all types of cognitive impairment (including dementia). Exclusion criteria were: reviews, abstracts, secondary Sjögren's syndrome (SS), and all articles in which other classification criteria were used.
RESULTS
RESULTS
The initial search yielded 352 articles, of which 253 were excluded based on the title and abstract review. A total of 54 articles underwent a full-length review, and 32 articles were excluded. Data were extracted from 18 studies and three case-reports involving a total of 6196 participants. In most cases, cognitive dysfunction was a brain fog or a mild cognitive impairment (MCI). Occasionally, an autoimmune dementia was present. The relationship between pSS and degenerative dementias, such as Alzheimer's disease (AD), was a controversial issue, even if some investigators hypothesized that pSS could be a risk factor. Several unmet needs were highlighted. First, some of the included studies had not reported the severity of pSS; hence, few correlations between disease severity and cognitive function were possible. Secondly, the evaluation of the pathogenetic role of comorbid diseases was often absent. The lack of information on the type of dementia represented a third critical point in the majority of the included studies.
CONCLUSIONS
CONCLUSIONS
This systematic review confirmed that adequate studies on cognitive function in pSS are scarce, mostly performed on small-sized samples, and often conflicting. The routine assessment of cognitive function in patients with pSS seems advisable and it will help to elucidate some of the unmet needs highlighted by this review in future appropriately designed studies.
Identifiants
pubmed: 30991679
pii: brainsci9040085
doi: 10.3390/brainsci9040085
pmc: PMC6523842
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Rheumatol. 1999 Jun;26(6):1301-5
pubmed: 10381047
Curr Rheumatol Rep. 2001 Apr;3(2):123-7
pubmed: 11286668
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
Medicine (Baltimore). 2004 Sep;83(5):280-91
pubmed: 15342972
Ann Rheum Dis. 2004 Oct;63(10):1335-7
pubmed: 15361396
J Neurol Sci. 2005 May 15;232(1-2):111-3
pubmed: 15850591
Rheumatology (Oxford). 2007 Dec;46(12):1845-51
pubmed: 18032543
J Neurol Sci. 2008 May 15;268(1-2):195-8
pubmed: 18234228
Ann Rheum Dis. 2010 Jan;69(1):132-7
pubmed: 19158115
Ann Rheum Dis. 2010 Jun;69(6):1103-9
pubmed: 19561361
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Musculoskeletal Care. 2010 Jun;8(2):107-17
pubmed: 20229610
J Rheumatol. 2010 Jun;37(6):1188-94
pubmed: 20360180
Clin Rheumatol. 2011 Apr;30(4):485-90
pubmed: 20393864
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Acta Neurol Scand. 2012 Apr;125(4):272-8
pubmed: 21651503
Ann Rheum Dis. 2012 May;71(5):668-73
pubmed: 22121127
Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87
pubmed: 22563590
J Neurol Sci. 2012 Nov 15;322(1-2):217-21
pubmed: 22901967
Reumatismo. 2012 Sep 28;64(4):206-15
pubmed: 23024965
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1291-8
pubmed: 23335582
Arthritis Rheum. 2013 Dec;65(12):3209-17
pubmed: 23982950
ISRN Neurol. 2013 Sep 19;2013:501327
pubmed: 24224097
Arq Neuropsiquiatr. 2014 Jan;72(1):38-43
pubmed: 24637981
Ann Rheum Dis. 2015 Nov;74(11):1983-9
pubmed: 24938285
Rheumatol Int. 2015 Feb;35(2):289-94
pubmed: 25056402
Clin Epidemiol. 2014 Jul 30;6:247-55
pubmed: 25114590
Neurol Sci. 2015 Sep;36(9):1589-95
pubmed: 25868598
Scand J Rheumatol. 2015;44(6):487-94
pubmed: 26271272
Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96):S9-13
pubmed: 26315451
RMD Open. 2015 Feb 20;1(1):e000022
pubmed: 26509054
Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96):S6-8
pubmed: 27049627
Int J Rheum Dis. 2016 Oct;19(10):981-988
pubmed: 27455357
Arthritis Rheumatol. 2017 Jan;69(1):35-45
pubmed: 27785888
Brain Behav. 2016 Oct 13;6(12):e00586
pubmed: 28032007
Clin Exp Rheumatol. 2017 Mar-Apr;35(2):255-261
pubmed: 28032845
BMC Med. 2017 Mar 31;15(1):69
pubmed: 28359271
Arthritis Res Ther. 2017 Dec 6;19(1):269
pubmed: 29208023
Clin Rheumatol. 2018 Apr;37(4):935-941
pubmed: 29243055
PLoS One. 2018 Jan 5;13(1):e0186475
pubmed: 29304089
N Engl J Med. 2018 Mar 08;378(10):931-939
pubmed: 29514034
Br J Occup Ther. 2018 Apr;81(4):218-226
pubmed: 29657352
BMC Neurosci. 2018 Apr 27;19(1):26
pubmed: 29703151
Reumatologia. 2018;56(2):99-105
pubmed: 29853725
Arch Med Sci. 2018 Jun;14(4):830-837
pubmed: 30002701
Curr Rheumatol Rev. 2018 Jul 30;:null
pubmed: 30062971
Musculoskeletal Care. 2019 Mar;17(1):97-104
pubmed: 30468553
Curr Treatm Opt Rheumatol. 2017 Dec;3(4):275-288
pubmed: 30627507
Eur J Case Rep Intern Med. 2018 Jun 26;5(6):000855
pubmed: 30756038
Front Immunol. 2019 Feb 26;10:312
pubmed: 30863411
Medicine (Baltimore). 1982 Jul;61(4):247-57
pubmed: 6283302